Incannex Sets Dec. 18 Annual Meeting; Board Seeks Director, Auditor Approval

TL;DR

**IXHL's upcoming annual meeting is a standard governance check, but pay attention to director elections for future strategic shifts.**

AI Summary

Incannex Healthcare Inc. (IXHL) is holding its 2025 Annual Meeting on December 18, 2025, in a hybrid format in Dubai, UAE, and virtually. Stockholders will vote on two key proposals: the election of two Class II directors for three-year terms expiring in 2028, and the ratification of Grant Thornton Audit Pty Ltd as the independent registered public accounting firm for the fiscal year ending June 30, 2026. The board of directors recommends a 'FOR' vote for both proposals. The company had 347,705,507 shares of common stock outstanding and entitled to vote as of the record date, October 24, 2025. Proxy materials are being distributed electronically starting October 31, 2025, to conserve resources and reduce costs. The company emphasizes the importance of stockholder participation, offering voting via internet, telephone, or mail, even if not attending the meeting.

Why It Matters

This DEF 14A filing outlines Incannex Healthcare Inc.'s governance structure and upcoming key decisions, directly impacting investor confidence and operational oversight. The election of Class II directors for three-year terms through 2028 will shape the company's strategic direction and accountability. Ratifying Grant Thornton Audit Pty Ltd as the auditor for fiscal year 2026 is crucial for financial transparency and regulatory compliance, which can influence market perception and competitive standing in the healthcare sector. For employees and customers, stable governance and clear financial reporting signal a reliable and well-managed company, fostering trust and long-term engagement.

Risk Assessment

Risk Level: low — The filing primarily concerns routine corporate governance matters, specifically the election of two Class II directors and the ratification of the independent auditor, Grant Thornton Audit Pty Ltd. There are no indications of contentious proposals, significant financial distress, or unusual changes in company operations or leadership, suggesting a low immediate risk to investors based solely on this proxy statement.

Analyst Insight

Investors should review the backgrounds of the director nominees to ensure alignment with their investment thesis and vote 'FOR' the ratification of Grant Thornton Audit Pty Ltd to maintain sound financial oversight. Participate in the hybrid meeting on December 18, 2025, if possible, to engage directly with management and the board.

Key Numbers

• 347,705,507 — Shares of Common Stock Outstanding (Entitled to vote as of the Record Date, October 24, 2025)
• 2 — Class II Directors (To be elected for three-year terms expiring in 2028)
• 2028 — Director Term Expiration Year (New Class II directors will serve until this year)
• 2026 — Fiscal Year for Auditor Appointment (Grant Thornton Audit Pty Ltd appointed for fiscal year ending June 30, 2026)
• October 24, 2025 — Record Date (Date for determining stockholders entitled to vote at the Annual Meeting)
• December 18, 2025 — Annual Meeting Date (Date of the 2025 Annual Meeting of Stockholders)
• October 31, 2025 — Proxy Materials Distribution Start Date (Date Incannex intends to begin sending Internet Availability Notice)

Key Players & Entities

• Incannex Healthcare Inc. (company) — Registrant and issuer of common stock
• Grant Thornton Audit Pty Ltd (company) — Independent registered public accounting firm for fiscal year ending June 30, 2026
• Troy Valentine (person) — Chairman of the Board of Directors
• Joseph Swan (person) — Secretary of Incannex Healthcare Inc.
• Securities and Exchange Commission (regulator) — Regulatory body for proxy statement filing
• Computershare Trust Company, N.A. (company) — Transfer agent for Incannex Healthcare Inc.
• 347,705,507 (dollar_amount) — Shares of common stock outstanding and entitled to vote on October 24, 2025

FAQ

Industry Context

Incannex Healthcare Inc. operates within the biotechnology and pharmaceutical sector, focusing on developing novel treatments using psychedelic compounds. This industry is characterized by significant research and development investment, stringent regulatory pathways (e.g., FDA, EMA), and a growing interest in alternative therapeutic approaches for conditions like anxiety, pain, and PTSD. The competitive landscape includes both established pharmaceutical companies and emerging biotechs exploring similar novel drug development.

Regulatory Implications

As a healthcare company, Incannex is subject to extensive regulatory oversight from bodies like the FDA and EMA concerning drug development, clinical trials, and eventual market approval. The use of psychedelic compounds introduces specific regulatory challenges and evolving guidelines. Successful navigation of these regulatory hurdles is critical for the company's product pipeline and market access.

What Investors Should Do

1. Vote on Director Elections
2. Ratify Auditor Appointment
3. Review Proxy Materials
4. Participate in the Annual Meeting

Key Dates

• 2025-10-24: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting.
• 2025-10-27: Date of Proxy Statement — Indicates the official date of the proxy materials being distributed.
• 2025-10-31: Proxy Materials Distribution Start Date — When stockholders can expect to receive or access proxy materials, enabling them to review information and vote.
• 2025-12-18: Annual Meeting Date — The date for the 2025 Annual Meeting of Stockholders where key proposals will be voted upon.
• 2026-06-30: Fiscal Year End — The end date for the fiscal year for which Grant Thornton Audit Pty Ltd is appointed as the independent registered public accounting firm.
• 2028-XX-XX: Director Term Expiration — The year when the terms of the newly elected Class II directors will expire, indicating the next election cycle for these positions.

Glossary

DEF 14A

A proxy statement filed with the SEC by domestic U.S. companies. It contains information about the annual meeting of shareholders, including details on director nominees, executive compensation, and matters to be voted on. (This document is the primary source of information for stockholders to understand the company's governance and upcoming voting matters.)

Proxy

A document that authorizes another person to act on behalf of the shareholder, typically to vote their shares at a shareholder meeting. (Stockholders can grant a proxy to the board of directors or another designated individual to vote their shares if they cannot attend the meeting.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (Establishes the pool of eligible voters for the December 18, 2025 Annual Meeting.)

Hybrid Format

A meeting format that allows for both in-person attendance and virtual participation. (Incannex is offering a hybrid meeting in Dubai and virtually, providing flexibility for stockholders to participate.)

Independent Registered Public Accounting Firm

An external accounting firm hired by a company to audit its financial statements and provide an independent opinion on their fairness and accuracy. (The ratification of Grant Thornton Audit Pty Ltd is a key proposal, ensuring the integrity of the company's financial reporting.)

Class II Directors

In a classified board structure, directors are divided into classes (e.g., Class I, II, III), with only one class up for election each year. This results in staggered terms. (Two Class II directors are up for election, with terms expiring in 2028, impacting the board's composition and governance.)

Year-Over-Year Comparison

This filing pertains to the 2025 Annual Meeting. Specific comparative financial data (e.g., revenue, net income) from the prior year's filing (likely for the fiscal year ended June 30, 2024) is not detailed within this proxy statement itself, which focuses on the upcoming meeting's proposals and governance. The proxy statement does reference the Annual Report for the fiscal year ended June 30, 2025, which would contain the most recent financial performance data.

Filing Documents

• ea0262409-def14a_incannex.htm (DEF 14A) — 296KB
• image_001.jpg (GRAPHIC) — 642KB
• image_002.jpg (GRAPHIC) — 595KB
• 0001213900-25-102654.txt ( ) — 3791KB
• ixhl-20251027.xsd (EX-101.SCH) — 10KB
• ixhl-20251027_def.xml (EX-101.DEF) — 2KB
• ixhl-20251027_lab.xml (EX-101.LAB) — 33KB
• ea0262409-def14a_incannex_htm.xml (XML) — 3KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 MANAGEMENT AND CORPORATE GOVERNANCE 9 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 15 EQUITY COMPENSATION PLAN INFORMATION 20 REPORT OF AUDIT COMMITTEE 24 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 25 PROPOSAL NO. 1 ELECTION OF CLASS II DIRECTORS 26 PROPOSAL NO. 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 27 CODE OF CONDUCT AND ETHICS 29 OTHER MATTERS 29 STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR 29 i Incannex Healthcare Inc. Rialto South Tower Level 23, 525 Collins Street Melbourne VIC 3008 Australia October 27, 2025 PROXY STATEMENT FOR INCANNEX HEALTHCARE INC. 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 18, 2025 This proxy statement, along with the accompanying Notice of 2025 Annual Meeting of Stockholders contains information about the 2025 annual meeting of stockholders of Incannex Healthcare Inc. (the "Annual Meeting"), including any adjournments or postponements of the Annual Meeting. We are holding the Annual Meeting in a hybrid format, both virtually via live audio webcast on the Internet by visiting www.meetnow.global/MD59M9U and in-person at Business Hub, Al Fattan Tower, 2 nd Floor, Jumeirah Beach Residence, Dubai, UAE. In this proxy statement, we refer to Incannex Healthcare Inc. as "Incannex," "the Company," "we" and "us." This proxy statement relates to the solicitation of proxies by our board of directors for use at the Annual Meeting. On or about October 31, 2025, we intend to begin sending to our stockholders the Important Notice Regarding the Availability of Proxy Materials containing instructions on how to access our proxy statement for our Annual Meeting and our 2025 annual report to stockholders . 1 IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON DECEMBER 18, 2025 This proxy statement, the Notice of 202

financial statements for the fiscal year ended June 30, 2025, on the website of the SEC at www.sec.gov , or in the

financial statements for the fiscal year ended June 30, 2025, on the website of the SEC at www.sec.gov , or in the "SEC Filings" section of the "Investors" section of our website at www.incannex.com. You may also obtain a printed copy of our Annual Report, including our financial statements, free of charge, from us by sending a written request to: Incannex Healthcare Inc., Attn: Investor Relations, Rialto South Tower Level 23, 525 Collins Street Melbourne VIC 3008Australia. Exhibits will be provided upon written request and payment of an appropriate processing fee. 2 IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING Why is the Company Soliciting My Proxy? Our board of directors is soliciting your proxy to vote at the Annual Meeting to be held in a hybrid format, both virtually via live audio webcast on the Internet by visiting www.meetnow.global/MD59M9U, inputting your 16-digit control number printed on your proxy card and by following the instructions on the website, and in-person at Business Hub, Al Fattan Tower, 2 nd Floor, Jumeirah Beach Residence, Dubai, UAE on Thursday, December 18, 2025, at 10:00 a.m. Gulf Standard Time ("GST"), and any adjournments or postponements of the meeting. This proxy statement, along with the accompanying Notice of 2025 Annual Meeting, summarizes the purposes of the meeting and the information you need to know to vote at the Annual Meeting. We have made available to you on the Internet or have sent you this proxy statement, the Notice of 2025 Annual Meeting, the proxy card and a copy of the Annual Report, because you owned shares of our common stock on October 24, 2025 (the "Record Date"). We intend to commence distribution of the Important Notice Regarding the Availability of Proxy Materials, which we refer to throughout this proxy statement as the Internet Availability Notice, and, if applicable, proxy materials to stockholders on or about October 31, 2025. Why Did I Receive a Notice in the Mail Regarding the I

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL The following table sets forth certain information with respect to the beneficial ownership of our common stock as of October 10, 2025 for (a) the executive officers named in the Summary Compensation Table included elsewhere in this proxy statement, (b) each of our directors and director nominees, and (c) all of our current directors and executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of October 10, 2025 pursuant to the exercise of options, warrants, or the vesting of restricted stock units ("RSUs") to be outstanding for the purpose of computing the percentage ownership of such individual or group, but those shares are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 347,705,507 shares of common stock outstanding on October 10, 2025. Unless otherwise indicated, the business address of each of the following individuals is c/o Incannex Healthcare Inc., Rialto South Tower Level 23, 525 Collins Street Melbourne VIC 3008 Australia. Shares Beneficially Owned Directors and Named Executive Officers: Number Percent Joel Latham (1) 1,686,822 * Troy Valentine (2) 1,084,284 * Peter Widdows (3) 281,897 * Dr. George Anastassov (4) 769,721 * Robert Clark (5) 100,

View Full Filing

View this DEF 14A filing on SEC EDGAR